6 references analysed. 2 serious problems 4 to fix

Publisher or catalogue metadata compared for 6 references. 0 unresolved references: this does not mean they are incorrect.

Corrected .bib

5 entries can be corrected. Untick below the corrections you do not want, then download.

Open in Overleaf: a new project prints every entry of the corrected .bib, to check that it compiles before replacing the .bib of your manuscript.

References

  • mehra2020 · Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis · 10.1016/s0140-6736(20)31180-6

    Retracted This paper has been retracted. Remove it, or cite it as retracted. Retraction notice
    Expression of concern The journal has published an expression of concern about this paper: check that you can still rely on it. Notice
    Correction published A correction to this paper has been published: check that it does not change what you cite. Correction
  • wakefield1998 · Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children · 10.1016/s0140-6736(97)11096-0

    Retracted This paper has been retracted. Remove it, or cite it as retracted. Retraction notice
    Correction published A correction to this paper has been published: check that it does not change what you cite. Correction
    Incomplete entry Added from the record that identifies it: doi = 10.1016/s0140-6736(97)11096-0.
    Suggested corrected entry — review before using

    Your entry

    @article{wakefield1998,
      title={Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children},
      author={Wakefield, A. J. and Murch, S. H. and Anthony, A. and others},
      journal={The Lancet},
      volume={351},
      pages={637--641},
      year={1998}
    }

    Corrected

    @article{wakefield1998,
      title = {Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children},
      author = {Wakefield, A. J. and Murch, S. H. and Anthony, A. and others},
      journal = {The Lancet},
      volume = {351},
      pages = {637--641},
      year = {1998},
      doi = {10.1016/s0140-6736(97)11096-0},
    }

  • routy2018 · Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors · 10.1126/science.aan3706

    Correction published A correction to this paper has been published: check that it does not change what you cite. Correction
    Reference to correct Record found in Crossref
    • Year : 2017 → 2018
    Suggested corrected entry — review before using

    Your entry

    @article{routy2018,
      title={Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors},
      author={Routy, Bertrand and Le Chatelier, Emmanuelle and Derosa, Lisa and others},
      journal={Science},
      volume={359},
      pages={91--97},
      year={2017}
    }

    Corrected

    @article{routy2018,
      title = {Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors},
      author = {Routy, Bertrand and Le Chatelier, Emmanuelle and Derosa, Lisa and others},
      journal = {Science},
      volume = {359},
      pages = {91--97},
      year = {2018},
      doi = {10.1126/science.aan3706},
    }

  • gopalakrishnan2018b · Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients · 10.1126/science.aan4236

    Duplicate The same paper as gopalakrishnan2018.
    Incomplete entry Added from the record that identifies it: doi = 10.1126/science.aan4236.
    Suggested corrected entry — review before using

    Your entry

    @article{gopalakrishnan2018b,
      title={Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients},
      author={Gopalakrishnan, Vancheswaran and Spencer, Christine N. and Nezi, Luigi and others},
      journal={Science},
      volume={359},
      pages={97--103},
      year={2018}
    }

    Corrected

    @article{gopalakrishnan2018b,
      title = {Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients},
      author = {Gopalakrishnan, Vancheswaran and Spencer, Christine N. and Nezi, Luigi and others},
      journal = {Science},
      volume = {359},
      pages = {97--103},
      year = {2018},
      doi = {10.1126/science.aan4236},
    }

  • gopalakrishnan2018 · Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients · 10.1126/science.aan4236

    Incomplete entry Added from the record that identifies it: doi = 10.1126/science.aan4236, volume = 359, pages = 97-103.
    Suggested corrected entry — review before using

    Your entry

    @article{gopalakrishnan2018,
      title={Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients},
      author={Gopalakrishnan, V. and Spencer, C. N. and Nezi, L. and others},
      journal={Science},
      year={2018}
    }

    Corrected

    @article{gopalakrishnan2018,
      title = {Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients},
      author = {Gopalakrishnan, V. and Spencer, C. N. and Nezi, L. and others},
      journal = {Science},
      year = {2018},
      doi = {10.1126/science.aan4236},
      volume = {359},
      pages = {97-103},
    }

  • sivan2015 · Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy · 10.1126/science.aac4255

    Incomplete entry Added from the record that identifies it: doi = 10.1126/science.aac4255, volume = 350, pages = 1084-1089, journal = Science.
    Suggested corrected entry — review before using

    Your entry

    @article{sivan2015,
      title={Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy},
      author={Sivan, Ayelet and Corrales, Leticia and Hubert, Nathaniel and others},
      year={2015}
    }

    Corrected

    @article{sivan2015,
      title = {Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy},
      author = {Sivan, Ayelet and Corrales, Leticia and Hubert, Nathaniel and others},
      year = {2015},
      doi = {10.1126/science.aac4255},
      volume = {350},
      pages = {1084-1089},
      journal = {Science},
    }

Your LaTeX and your .bib

Missing from the .bib Your LaTeX cites these keys, which your .bib does not define: they will print as [?].

taylor2014

Profile of your bibliography
  • Median age of the references: 8 years (from 1998 to 2020). 0 of 6 dated references are from the last five years.
  • 0 references cited as preprints. 6 of 6 references have a DOI or an arXiv identifier.
  • Most cited venues: Science (3), The Lancet (2).

For information: referees often look at how recent the references are and how many are self-citations. Nothing here is an error.

Citations to check

2 sentences with citations read out of 4: those that attribute a result, a value or a method to a paper first. Each sentence is read with the abstracts of all the papers it cites; those flagged are read again against the full text of the papers when it may be read. A flagged citation may be right: check it in the paper. Full texts read: 0 of the 4 papers concerned (the others are closed to text mining or could not be fetched).

  • The abstract says otherwise cited for a result · main.tex, line 6
    Routy et al. showed that antibiotic treatment improved the response of patients with epithelial tumours to PD-1 blockade [routy2018].

    L’abstract associe la consommation d’antibiotiques à une mauvaise réponse au blocage de PD-1, et non à une amélioration de celle-ci.

    routy2018 · Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
    Abstract

    Good bacteria help fight cancer Resident gut bacteria can affect patient responses to cancer immunotherapy (see the Perspective by Jobin). Routy et al. show that antibiotic consumption is associated with poor response to immunotherapeutic PD-1 blockade. They profiled samples from patients with lung and kidney cancers and found that nonresponding patients had low levels of the bacterium Akkermansia muciniphila . Oral supplementation of the bacteria to antibiotic-treated mice restored the response to immunotherapy. Matson et al. and Gopalakrishnan et al. studied melanoma patients receiving PD-1 blockade and found a greater abundance of “good” bacteria in the guts of responding patients. Nonresponders had an imbalance in gut flora composition, which correlated with impaired immune cell activity. Thus, maintaining healthy gut flora could help patients combat cancer. Science , this issue p. 91 , p. 104 , p. 97 ; see also p. 32

  • Not in the abstract cited for a result · main.tex, line 7
    Commensal Bifidobacterium promotes antitumour immunity in mice [sivan2015], and responders carry a more diverse gut microbiome [gopalakrishnan2018, gopalakrishnan2018b].

    Si l’effet antitumoral de Bifidobacterium chez la souris est étayé, les abstracts de Gopalakrishnan mentionnent une plus grande abondance de bactéries bénéfiques chez les répondeurs sans préciser une diversité accrue du microbiome.

    gopalakrishnan2018 · Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
    Abstract

    Good bacteria help fight cancer Resident gut bacteria can affect patient responses to cancer immunotherapy (see the Perspective by Jobin). Routy et al. show that antibiotic consumption is associated with poor response to immunotherapeutic PD-1 blockade. They profiled samples from patients with lung and kidney cancers and found that nonresponding patients had low levels of the bacterium Akkermansia muciniphila . Oral supplementation of the bacteria to antibiotic-treated mice restored the response to immunotherapy. Matson et al. and Gopalakrishnan et al. studied melanoma patients receiving PD-1 blockade and found a greater abundance of “good” bacteria in the guts of responding patients. Nonresponders had an imbalance in gut flora composition, which correlated with impaired immune cell activity. Thus, maintaining healthy gut flora could help patients combat cancer. Science , this issue p. 91 , p. 104 , p. 97 ; see also p. 32

    gopalakrishnan2018b · Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
    Abstract

    Good bacteria help fight cancer Resident gut bacteria can affect patient responses to cancer immunotherapy (see the Perspective by Jobin). Routy et al. show that antibiotic consumption is associated with poor response to immunotherapeutic PD-1 blockade. They profiled samples from patients with lung and kidney cancers and found that nonresponding patients had low levels of the bacterium Akkermansia muciniphila . Oral supplementation of the bacteria to antibiotic-treated mice restored the response to immunotherapy. Matson et al. and Gopalakrishnan et al. studied melanoma patients receiving PD-1 blockade and found a greater abundance of “good” bacteria in the guts of responding patients. Nonresponders had an imbalance in gut flora composition, which correlated with impaired immune cell activity. Thus, maintaining healthy gut flora could help patients combat cancer. Science , this issue p. 91 , p. 104 , p. 97 ; see also p. 32